Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyIoannis Ntanasis‐Stathopoulos, Evangelos Terpos, Vangelis Karalis et al.|HemaSphere|2022Cited by 44
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic EventsEvangelos Terpos, Meletios Α. Dimopoulos, Despina Fotiou et al.|Vaccines|2021Cited by 30
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222Evangelos Terpos, Meletios Α. Dimopoulos, Despoina D. Gianniou et al.|Biomedicines|2022Cited by 29
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy IndividualsEvangelos Terpos, Meletios Α. Dimopoulos, Vangelis Karalis et al.|Life|2021Cited by 28